Company
Kyowa Kirin
Kyowa Kirin has 46 drugs tracked on RxWires: 4 post-market, 12 in Phase 3, 1 in Phase 2/3, 10 in Phase 2, 3 in Phase 1/2, 16 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Mogamulizumab | Post-Market | Cutaneous T-Cell Lymphoma |
| Istradefylline Pill | Post-Market | Parkinson Disease |
| KRN23 | Post-Market | Tumor-Induced Osteomalacia (TIO) |
| Brodalumab 210mg SC | Post-Market | Psoriasis Vulgaris |
| KW-2246 (fentanyl citrate) | Phase 3 | Pain, Cancer |
| KHK4827 | Phase 3 | Psoriasis |
| KW-0761 | Phase 3 | Cutaneous T-Cell Lymphoma |
| KK8398 | Phase 3 | Achondroplasia |
| Istradefylline ( KW-6002) | Phase 3 | Parkinson's Disease |
| Istradefylline 20 mg or 40 mg | Phase 3 | Idiopathic Parkinson's Disease |
| KW-6500 | Phase 3 | Parkinson's Disease |
| Burosumab | Phase 3 | X-linked Hypophosphatemia |
| EN3267 | Phase 3 | Pain |
| OPC-262 | Phase 3 | Type 2 Diabetes |
| darbepoetin alfa | Phase 3 | Anemia |
| KHK7791 | Phase 3 | Hyperphosphatemia |
| Romiplostim | Phase 2/3 | Aplastic Anemia |
| KRN125(pegfilgrastim), PLR001(plerixafor) | Phase 2 | Multiple Myeloma and Malignant Lymphoma |
| KHK4563 | Phase 2 | Uncontrolled and Suspected Eosinophilic Asthma |
| RTA 402 | Phase 2 | Chronic Kidney Disease |
| Istradefylline medication | Phase 2 | Parkinson Disease |
| KHK4951 | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) |
| ziftomenib | Phase 2 | Acute Myeloid Leukemia (AML) |
| ME-401 | Phase 2 | Indolent B-cell Non-Hodgkin's Lymphoma |
| ARQ 197 | Phase 2 | Non-small-cell Lung Cancer |
| Granisetron | Phase 2 | Gastroparesis |
| AMG531 | Phase 2 | Aplastic Anemia |
| KRN7000 | Phase 1/2 | Chronic Hepatitis C |
| KK8123 | Phase 1/2 | X-linked Hypophosphatemia |
| KK2430 | Phase 1/2 | Hematologic Neoplasms |
| Sancuso | Phase 1 | Chemotherapy Induced Nausea and Vomiting |
| Naloxegol | Phase 1 | Constipation, Signs and Symptoms, Digestive |
| KHK6640 | Phase 1 | Alzheimer Disease |
| KK2260 | Phase 1 | Advanced or Metastatic Solid Tumors |
| KK3910 | Phase 1 | |
| KK2223 | Phase 1 | T-cell NHL (PTCL or CTCL) |
| KK2845_1 | Phase 1 | Relapsed or Refractory AML and Other Hematologic Malignancies |
| KK4277 | Phase 1 | Systemic Lupus Erythematosus (SLE) |
| KHK4083 | Phase 1 | Dermatitis, Atopic |
| KK2269 | Phase 1 | Advanced Solid Tumor |
| KW-6356 | Phase 1 | Healthy Male Subjects |
| KRN951 | Phase 1 | Solid Tumors |
| KHK4323 IV/S | Phase 1 | Atopic Dermatitis |
| ARQ197 | Phase 1 | Cancer |
| granisetron transdermal system | Phase 1 | Chemotherapy Induced Nausea and Vomiting |
| Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558) | Phase 1 | Solid Tumor |
Latest
No recent events.
Follow Kyowa Kirin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.